Page 15 - Biocon

Coronavirus LIVE: 22k new cases in Kerala in a day; 6,258 in Maharashtra

India recorded 29,689 new coronavirus infections on Tuesday, which pushed its tally of Covid-19 cases to 31,440,951

Biocon partners Adagio for licence to make Covid-19 antibody cocktail

Treatment claims to address the resistant Delta variant as well

Biocon Biologics gets licence from Adagio for antibody Covid treatment

Initial data indicate that ADG20 could provide both rapid and durable protection against Covid-19 for up to one year

Biocon likely to seek full marketing authorisation for Covid-19 drug

Expects results from phase 4 study of itolizumab by end of this quarter

Biocon Q1 net profit declines 35% to Rs 108.4 cr; revenue at Rs 1807.8 cr

Biotechnology major Biocon has reported a 35.39 per cent decline in its consolidated net profit at Rs 108.4 crore for the quarter ended June 30, 2021 mainly on account of its share of loss in associate startup entity Bicara Therapeutics Inc. The company had posted a net profit of Rs 167.8 crore for the corresponding period of the previous fiscal, Biocon said in a late night filing on Thursday. Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was Rs 1,712.1 crore for the same period a year ago, it added. "Consolidated revenues, at Rs 1,808 crore, saw a muted growth on account of COVID-related operational challenges at Biocon's API facilities, both in Bengaluru and Hyderabad," Biocon Executive Chairperson Kiran Mazumdar-Shaw said. Q1FY22 P&L was also impacted by a share of loss in its Boston-based associate start-up entity, Bicara Therapeutics Inc, she added. "The outlook for the rest of the year is promising with several drug ...

Stocks to watch: Zomato, RIL, SBI Card, Voda Idea, Airtel, BPCL, Biocon

Forty-one companies, including RIL, JSW Steel, SBI Card, YES Bank and Federal Bank will report their quarterly numbers today

Top headlines: Parliament meets, firms face heat on independent valuation

Here are the top headlines on Monday morning

Biocon controversy: Sebi's insider trading laws may need an overhaul

Sebi regulations define "insider" as a company associate who is trading in the company's shares based on unpublished price sensitive information (UPSI) to make a quick buck

'Christie fiction': Biocon chief slams Sebi order on Allegro Capital

The case dates back to January 2018, when Biocon had announced an exclusive global collaboration with Sandoz on next-generation biosimilars

Sebi bars Allegro Capital for insider trading activities in Biocon shares

Sebi has barred Allegro Capital and one of its senior executives from the securities market for one year

Sebi bars Biocon's official from securities mkt for 3 months, levies fine

Regulator Sebi has restrained an official of Biocon Ltd from accessing the securities market for three months and also levied monetary penalty for contravening insider trading norms. Biocon had announced information relating to its collaboration with Sandoz and the period of unpublished price sensitive information (UPSI) was from December 20, 2017 to January 18, 2018, The Securities and Exchange Board of India (Sebi) noted in an order passed late on Wednesday. Senior vice president of Biocon, Shreehas P Tambe, being an insider traded in the shares of the firm between December 19-27, 2017, in violation of market norms. Besides, Tambe also failed to make the timely requisite disclosures to Biocon pertaining to the trade for the sale of shares on December 19 and 20, 2017, where the sell value was more than Rs 10 lakh. As part of mandatory obligation under Prohibition of Insider Trading norms, Tambe was required to make disclosure within two trading days from the date of sale of shares

Covid has created an ecosystem of innovation in India: Kiran Mazumdar-Shaw

The ongoing Covid-19 public health crisis has resulted in the creation of an "ecosystem" of innovation in India, Biocon chief Kiran Mazumdar-Shaw has said

Sebi fines Biocon, its designated person for violating market norms

Markets regulator Sebi on Wednesday imposed a total fine of Rs 14 lakh on Biocon Ltd and its designated person for violation of market norms. Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh for trading in the company's securities when the trading window was closed. By doing so, he violated provisions of Prohibition of Insider Trading (PIT) norms. Sebi noted that the trading window was closed by the compliance officer of Biocon from January 1-26, 2019 on account of declaration of quarterly financial results of the company for the quarter ended December 31, 2018, which were announced on January 24, 2019. In accordance with market norms, the company has to notify the particulars of the trading details of the promoter / member of the promoter group /designated person /director, if the value of the securities traded is in excess of Rs 10 lakh, to the stock exchange within 2 trading days of ...

Biocon chief expresses concern over Covid-19 vaccine shortage

Biocon Executive Chairman Kiran Mazumdar-Shaw has expressed concern over shortage of Covid-19 vaccines and sought better transparency from the government.

Second wave of Covid-19 has hit India 'like a tsunami': Kiran Mazumdar Shaw

The unprecedented spike in coronavirus cases to the recent state elections and religious festivals in the country, says Kiran Mazumdar Shaw

Covid second wave has hit India 'like a tsunami' says Kiran Mazumdar Shaw

Biocon founder Kiran Mazumdar Shaw attributed the unprecedented spike in coronavirus cases to the recent state elections and religious festivals in the country

Amid weak showing by biosimilars and generics, downgrade pressure on Biocon

Analysts expect ramp-up in biosimilars to be gradual

Govt should have built safety stock of essential drugs: Kiran Mazumdar-Shaw

The Biocon founder and Executive Chairperson points out that drugs like Remdesivir should be allowed at home as an emergency step

Biotechnology major Biocon Q4 net profit surges 86% to Rs 296.4 crore

Biocon has reported 86.29% jump in consolidated profit to Rs 296.4 crore for the quarter ended March 31, 2021

Nifty outlook & trading ideas by Gaurav Garg of CapitalVia Global Research

Nifty index can witness profit booking only if it breaks level of 14,800